Oriola Corporation Investor news 22 November 2019 at 8.00 a.m.
Oriola and MSD renew their distribution agreement in Finland
Oriola and pharmaceutical company MSD Finland Oy have signed a new distribution agreement for the Finnish market. According to the agreement, Oriola continues to provide warehousing and distribution services for MSD Finland Oy’s human medicines in Finland. The wholesales value of MSD Finland Oy's human pharmaceuticals was in Finland approximately 170 million euro in 2018 and market share of the Finnish pharmaceutical market approximately 6,6% in 2018 (source: IMS Health).
Oriola announced in September a new contract with MSD Sverige AB’s human medicines wholesale and distribution for Swedish market.
“We are very pleased to be both MSD Finland Oy’s and MSD Sverige AB’s partner for reliable pharmaceutical distribution. Our common goal is to secure high quality and efficient pharmaceutical distribution for the Finnish and Swedish markets. We are developing our distribution capabilities constantly to meet highly regulated pharmaceutical distribution requirements as well as sustainable delivery practices,” says Thomas Gawell, VP, Business Area Pharma, Oriola.
“MSD Finland Oy is pleased to be continuing our longstanding relationship with Oriola providing our pharmaceutical products that improve and save lives. Given this important work for the betterment of public health, it is critical to have a trusted partner in place,” says Patricia Drake, Managing Director of MSD Finland Oy.
MSD is a global pharmaceutical company innovating within many therapeutic areas such as oncology, vaccines, infectious diseases as well as animal health products.
Oriola is responsible for nearly half of pharmaceutical distribution in Finland. It delivers pharmaceuticals for pharmacies, hospitals as well as other healthcare operators all over Finland. Additionally, Oriola sells and markets health and wellbeing products as well as veterinary pharmaceuticals and products for pharmacies, veterinaries and other retail operators. Oriola is also reliable expert partner for many pharmaceutical companies with wide range of expert services from Real World Evidence research to market access services.
Group Communications Director
Tel. +358 40 5885 343